Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC) - The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects - The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Metastatic Hepatocellular Carcinoma (HCC) Overview 9 Therapeutics Development 10 Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 10 Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 11 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 12 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 14 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 17 Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 18 Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 19 Acceleron Pharma, Inc. 19 AstraZeneca Plc 20 AVEO Pharmaceuticals, Inc. 21 Celgene Corporation 22 Eli Lilly and Company 23 F. Hoffmann-La Roche Ltd. 24 HanAll Biopharma Co., Ltd. 25 Incuron, LLC 26 Johnson & Johnson 27 Mirna Therapeutics, Inc. 28 Molecular Partners AG 29 MolMed S.p.A. 30 Novartis AG 31 OncoMed Pharmaceuticals, Inc. 32 Pfizer Inc. 33 PharmAbcine, Inc. 34 Verlyx Pharma Inc. 35 Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 AV-203 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 AZD-9150 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CC-122 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 codrituzumab - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 dalantercept - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 emibetuzumab - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 erdafitinib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 HL-143 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ipafricept - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LY-3039478 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 LY-3127804 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 mepacrine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 MP-0250 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 MRX-34 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NGR-hTNF - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 OSU-2S - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 palbociclib - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pasireotide - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pentamidine isethionate - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 PF-04518600 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 sonidegib phosphate - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 temsirolimus - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TTAC-0001 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates 91 Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 119 Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 120 Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 121 Featured News & Press Releases 121 Nov 20, 2014: ISIS-STAT3 Rx Data Presented by AstraZeneca at European Cancer Symposium 121 Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 122 May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 122 Appendix 123 Methodology 123 Coverage 123 Secondary Research 123 Primary Research 123 Expert Panel Validation 123 Contact Us 123 Disclaimer 124
List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2016 10 Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H1 2016 19 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H1 2016 20 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 21 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H1 2016 22 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H1 2016 23 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 25 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Incuron, LLC, H1 2016 26 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H1 2016 27 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H1 2016 28 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H1 2016 29 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H1 2016 30 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H1 2016 31 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 32 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H1 2016 33 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H1 2016 34 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H1 2016 91 Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H1 2016 119 Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H1 2016 120
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
